SAN DIEGO -- Patients with mantle cell lymphoma (MCL) and undetectable minimal residual disease (uMRD) after induction therapy did not live longer if they underwent hematopoietic cell transplantation ...

BOULDER, Colo., Dec. 3, 2025 /PRNewswire/ -- Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple ...

This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. "This milestone represents a transformative moment in ...

The ALPHA3 trial is exploring cemacabtagene ansegedleucel's (cema-cel) potential to enhance outcomes in patients who have relapsed/refractory large B-cell lymphoma, particularly those positive for ...

BOULDER, Colo.--(BUSINESS WIRE)--Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) testing, today announced the presentation of multiple studies showcasing Foresight ...

Please provide your email address to receive an email when new articles are posted on . HSCT did not benefit patients with mantle cell lymphoma in complete remission with undetectable minimal residual ...

Allogene Therapeutics has announced an expanded collaboration with Foresight Diagnostics to develop a minimal residual disease (MRD) assay as a companion diagnostic tool for identifying patients with ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...

Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and monitoring based on disease characteristics. Testing for minimal residual disease ...

Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a ...